Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization
| Autor: | Kathryn E Slane, Melissa A. Reimers, Russell K. Pachynski |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Male medicine.medical_specialty Urology medicine.medical_treatment Immune checkpoint inhibitors 030232 urology & nephrology Cell Cycle Proteins Cancer Vaccines 03 medical and health sciences Prostate cancer 0302 clinical medicine Antineoplastic Agents Immunological Castration Resistance Internal medicine medicine Humans Prostvac business.industry Tissue Extracts Immunotherapy Active General Medicine Immunotherapy medicine.disease GVAX Vaccine therapy Clinical trial Prostatic Neoplasms Castration-Resistant 030220 oncology & carcinogenesis business |
| Zdroj: | Current urology reports. 20(10) |
| ISSN: | 1534-6285 |
| Popis: | To date, prostate cancer has been poorly responsive to immunotherapy. In the current review, we summarize and discuss the current literature on the use of vaccine therapy and checkpoint inhibitor immunotherapy in metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T currently remains the only FDA-approved immunotherapeutic agent for prostate cancer. Single-agent phase 3 vaccine trials with GVAX and PROSTVAC have failed to demonstrate survival benefit to date. Clinical trials using combination approaches, including combination PROSTVAC along with a neoantigen vaccine and checkpoint inhibitor immunotherapy, are ongoing. Checkpoint inhibitor monotherapy clinical trials have demonstrated limited efficacy in advanced prostate cancer, and combination approaches and molecular patient selection are currently under investigation. The optimal use of vaccine therapy and checkpoint inhibitor immunotherapy in metastatic castration-resistant prostate cancer remains to be determined. Ongoing clinical trials will continue to inform future clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink